CKD Stage 4 Clinical Trial
Official title:
Ketoanalogue-supplemented Low Protein Diet and Deferring Dialysis in Patients With Severe Proteinuria and Advanced Diabetic Kidney Disease
This is a prospective single center open label randomized controlled trial aiming to assess
the effectiveness and safety of a low protein diet (0.6 g/kg-day, mainly vegetarian)
supplemented with ketoanalogues of essential amino-acids (sLPD) as compared to a mild protein
restriction (0.8 g/kg-day, MPD) in reducing Chronic Kidney Disease (CKD) progression, with a
planned total duration is of 18 months.
Adult diabetic patients with CKD stage 4+ [estimated glomerular filtration rate (eGFR) using
the Modification of Diet in Renal Disease 4-variable (MDRD4) formula <30 mL/min per year],
with stable renal function (historical reduction of eGFR of < 10 ml/min-year) , proteinuria >
3g/g creatininuria and good nutritional status (SGA A) will be enrolled.
Adult diabetic patients with Chronic Kidney Disease (CKD) stage 4+ (estimated GFR using the
Modification of Diet in Renal Disease 4-variable, MDRD4, formula <30 mL/min per year), with
stable renal function (historical reduction of eGFR of < 10 ml/min-year), proteinuria > 3g/g
creatininuria and good nutritional status (SGA A) will be enrolled. Patients with evidence of
active kidney disease (except proteinuria), with indication of etiological or pathogenic
treatment, those with poor control of diabetes (HbA1c >8%), those with uncontrolled high
blood pressure (≥155/85 mmHg), those with significant co-morbidities (heart failure, active
liver disease, malabsorption, active infections, inflammatory diseases requiring
corticosteroids), those with uremic symptoms (pericarditis, digestive disorders ) or
malnutrition (SGA B or C, serum albumin < 3.5 g/dl) will be excluded.
Eligible patients will enter a run-in phase (3 mo), when mild protein restriction (0.8g/kg
dry ideal bw) will be initiated and compliance will be evaluated twice monthly.
Those who will prove compliant during the run-in phase and still fulfill the selection
criteria will be randomized 1:1 (computer-generated numbers) to receive the low protein diet
(0.6 g/kg-day, mainly vegetarian) supplemented with ketoanalogues of essential amino-acids
(Ketosteril 1 tb/10 kg dry bw) or to continue the mild protein restriction (0.8 g/kg-day).
The total recommended energy intake is of 30 kcal/kg of ideal dry body weight per day in all
patients.
The primary composite endpoint is the need for RRT initiation or a more than 50% reduction in
the initial eGFR any time during the assessment phase. The decision to initiate RRT will be
made by the Ethical Committee of the Hospital, based on the clinical and laboratory data.
The need for RRT initiation, the quality of life [assessed by the Short Form-36 (SF-36)
Questionnaire], the decline in GFR and the correction of metabolic complications of CKD
[serum levels of urea, calcium, phosphates, serum parathyroid hormone levels, bicarbonate,
potassium] will be secondary efficacy parameters.
Parameters of nutritional status (SGA, anthropometric and biochemical parameters), compliance
to the diet, occurrence of any adverse event and the number of withdrawals will be safety
variables.
All the parameters will be assessed at baseline, throughout the intervention phase and at end
of the study.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03596749 -
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
|
Phase 3 | |
Not yet recruiting |
NCT05514184 -
Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
|
N/A | |
Not yet recruiting |
NCT04102319 -
Serum Hepcidin, Haemoglobin Level and Iron Status in Chronic Kidney Disease Patients (CKD) With Anaemia
|
||
Recruiting |
NCT05309785 -
Safety and Efficacy of Canagliflozin in Advanced CKD
|
Phase 4 | |
Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
Completed |
NCT05705011 -
Frailty, Cognitive Function and Health-related Quality of Life in Older Adults With Advanced Chronic Kidney Disease.
|
||
Completed |
NCT03588884 -
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
|
Phase 4 | |
Enrolling by invitation |
NCT06083545 -
The Effects of Application Intervention on the Physiological Indicators and Low Protein Diet Cognition Among the Patients With Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT05508009 -
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
|
Phase 1/Phase 2 | |
Recruiting |
NCT04633304 -
A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)
|
N/A | |
Completed |
NCT04862715 -
The Iron and Muscle Study
|
Phase 4 |